Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus. In 2005, they partnered with the Serum Institute of India Limited (SIIL), one of the largest vaccine manufacturers in the world, to produce the affordable RotaSIIL vaccines in India for use in developing countries. The vaccine is suitable for use in developing countries, lasting up to two years without refrigeration. The government of India has ordered 3.8 million doses for their Universal Immunization Programme.